A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia
Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose–response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid...
Saved in:
| Published in | Nutrients Vol. 15; no. 3; p. 492 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
17.01.2023
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2072-6643 2072-6643 |
| DOI | 10.3390/nu15030492 |
Cover
| Abstract | Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose–response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid profile and other metabolic markers in a dose-response manner in individuals with dyslipidemia. A total of 168 subjects were randomly assigned to placebo (n = 43) and resveratrol treatment groups of 100 mg/d (n = 41), 300 mg/d (n = 43), and 600 mg/d (n = 41). Anthropometric and biochemical parameters were analyzed at baseline and 4 and 8 weeks. Resveratrol supplementation for 8 weeks did not significantly change the lipid profile compared with the placebo. However, a significant decrease of serum uric acid was observed at 8 weeks in 300 mg/d (−23.60 ± 61.53 μmol/L, p < 0.05) and 600 mg/d resveratrol groups (−24.37 ± 64.24 μmol/L, p < 0.01) compared to placebo (8.19 ± 44.60 μmol/L). Furthermore, xanthine oxidase (XO) activity decreased significantly in the 600 mg/d resveratrol group (−0.09 ± 0.29 U/mL, p < 0.05) compared with placebo (0.03 ± 0.20 U/mL) after 8 weeks. The reduction of uric acid and XO activity exhibited a dose–response relationship (p for trend, <0.05). Furthermore, a marked correlation was found between the changes in uric acid and XO activity in the resveratrol groups (r = 0.254, p < 0.01). Resveratrol (10 μmol/L) treatment to HepG2 cells significantly reduced the uric acid levels and intracellular XO activity. Nevertheless, we failed to detect significant differences in glucose, insulin, or oxidative stress biomarkers between the resveratrol groups and placebo. In conclusion, resveratrol supplementation for 8 weeks had no significant effect on lipid profile but decreased uric acid in a dose-response manner, possibly due to XO inhibition in subjects with dyslipidemia. The trial was registered on ClinicalTrials.gov (NCT04886297). |
|---|---|
| AbstractList | Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose-response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid profile and other metabolic markers in a dose-response manner in individuals with dyslipidemia. A total of 168 subjects were randomly assigned to placebo (
= 43) and resveratrol treatment groups of 100 mg/d (
= 41), 300 mg/d (
= 43), and 600 mg/d (
= 41). Anthropometric and biochemical parameters were analyzed at baseline and 4 and 8 weeks. Resveratrol supplementation for 8 weeks did not significantly change the lipid profile compared with the placebo. However, a significant decrease of serum uric acid was observed at 8 weeks in 300 mg/d (-23.60 ± 61.53 μmol/L,
< 0.05) and 600 mg/d resveratrol groups (-24.37 ± 64.24 μmol/L,
< 0.01) compared to placebo (8.19 ± 44.60 μmol/L). Furthermore, xanthine oxidase (XO) activity decreased significantly in the 600 mg/d resveratrol group (-0.09 ± 0.29 U/mL,
< 0.05) compared with placebo (0.03 ± 0.20 U/mL) after 8 weeks. The reduction of uric acid and XO activity exhibited a dose-response relationship (
for trend, <0.05). Furthermore, a marked correlation was found between the changes in uric acid and XO activity in the resveratrol groups (
= 0.254,
< 0.01). Resveratrol (10 μmol/L) treatment to HepG2 cells significantly reduced the uric acid levels and intracellular XO activity. Nevertheless, we failed to detect significant differences in glucose, insulin, or oxidative stress biomarkers between the resveratrol groups and placebo. In conclusion, resveratrol supplementation for 8 weeks had no significant effect on lipid profile but decreased uric acid in a dose-response manner, possibly due to XO inhibition in subjects with dyslipidemia. The trial was registered on ClinicalTrials.gov (NCT04886297). Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose–response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid profile and other metabolic markers in a dose-response manner in individuals with dyslipidemia. A total of 168 subjects were randomly assigned to placebo (n = 43) and resveratrol treatment groups of 100 mg/d (n = 41), 300 mg/d (n = 43), and 600 mg/d (n = 41). Anthropometric and biochemical parameters were analyzed at baseline and 4 and 8 weeks. Resveratrol supplementation for 8 weeks did not significantly change the lipid profile compared with the placebo. However, a significant decrease of serum uric acid was observed at 8 weeks in 300 mg/d (−23.60 ± 61.53 μmol/L, p < 0.05) and 600 mg/d resveratrol groups (−24.37 ± 64.24 μmol/L, p < 0.01) compared to placebo (8.19 ± 44.60 μmol/L). Furthermore, xanthine oxidase (XO) activity decreased significantly in the 600 mg/d resveratrol group (−0.09 ± 0.29 U/mL, p < 0.05) compared with placebo (0.03 ± 0.20 U/mL) after 8 weeks. The reduction of uric acid and XO activity exhibited a dose–response relationship (p for trend, <0.05). Furthermore, a marked correlation was found between the changes in uric acid and XO activity in the resveratrol groups (r = 0.254, p < 0.01). Resveratrol (10 μmol/L) treatment to HepG2 cells significantly reduced the uric acid levels and intracellular XO activity. Nevertheless, we failed to detect significant differences in glucose, insulin, or oxidative stress biomarkers between the resveratrol groups and placebo. In conclusion, resveratrol supplementation for 8 weeks had no significant effect on lipid profile but decreased uric acid in a dose-response manner, possibly due to XO inhibition in subjects with dyslipidemia. The trial was registered on ClinicalTrials.gov (NCT04886297). Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose-response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid profile and other metabolic markers in a dose-response manner in individuals with dyslipidemia. A total of 168 subjects were randomly assigned to placebo (n = 43) and resveratrol treatment groups of 100 mg/d (n = 41), 300 mg/d (n = 43), and 600 mg/d (n = 41). Anthropometric and biochemical parameters were analyzed at baseline and 4 and 8 weeks. Resveratrol supplementation for 8 weeks did not significantly change the lipid profile compared with the placebo. However, a significant decrease of serum uric acid was observed at 8 weeks in 300 mg/d (-23.60 ± 61.53 μmol/L, p < 0.05) and 600 mg/d resveratrol groups (-24.37 ± 64.24 μmol/L, p < 0.01) compared to placebo (8.19 ± 44.60 μmol/L). Furthermore, xanthine oxidase (XO) activity decreased significantly in the 600 mg/d resveratrol group (-0.09 ± 0.29 U/mL, p < 0.05) compared with placebo (0.03 ± 0.20 U/mL) after 8 weeks. The reduction of uric acid and XO activity exhibited a dose-response relationship (p for trend, <0.05). Furthermore, a marked correlation was found between the changes in uric acid and XO activity in the resveratrol groups (r = 0.254, p < 0.01). Resveratrol (10 μmol/L) treatment to HepG2 cells significantly reduced the uric acid levels and intracellular XO activity. Nevertheless, we failed to detect significant differences in glucose, insulin, or oxidative stress biomarkers between the resveratrol groups and placebo. In conclusion, resveratrol supplementation for 8 weeks had no significant effect on lipid profile but decreased uric acid in a dose-response manner, possibly due to XO inhibition in subjects with dyslipidemia. The trial was registered on ClinicalTrials.gov (NCT04886297).Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose-response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid profile and other metabolic markers in a dose-response manner in individuals with dyslipidemia. A total of 168 subjects were randomly assigned to placebo (n = 43) and resveratrol treatment groups of 100 mg/d (n = 41), 300 mg/d (n = 43), and 600 mg/d (n = 41). Anthropometric and biochemical parameters were analyzed at baseline and 4 and 8 weeks. Resveratrol supplementation for 8 weeks did not significantly change the lipid profile compared with the placebo. However, a significant decrease of serum uric acid was observed at 8 weeks in 300 mg/d (-23.60 ± 61.53 μmol/L, p < 0.05) and 600 mg/d resveratrol groups (-24.37 ± 64.24 μmol/L, p < 0.01) compared to placebo (8.19 ± 44.60 μmol/L). Furthermore, xanthine oxidase (XO) activity decreased significantly in the 600 mg/d resveratrol group (-0.09 ± 0.29 U/mL, p < 0.05) compared with placebo (0.03 ± 0.20 U/mL) after 8 weeks. The reduction of uric acid and XO activity exhibited a dose-response relationship (p for trend, <0.05). Furthermore, a marked correlation was found between the changes in uric acid and XO activity in the resveratrol groups (r = 0.254, p < 0.01). Resveratrol (10 μmol/L) treatment to HepG2 cells significantly reduced the uric acid levels and intracellular XO activity. Nevertheless, we failed to detect significant differences in glucose, insulin, or oxidative stress biomarkers between the resveratrol groups and placebo. In conclusion, resveratrol supplementation for 8 weeks had no significant effect on lipid profile but decreased uric acid in a dose-response manner, possibly due to XO inhibition in subjects with dyslipidemia. The trial was registered on ClinicalTrials.gov (NCT04886297). Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy and dose–response relationship in clinical trials remains unclear. This study examined whether resveratrol supplement improves the serum lipid profile and other metabolic markers in a dose-response manner in individuals with dyslipidemia. A total of 168 subjects were randomly assigned to placebo ( n = 43) and resveratrol treatment groups of 100 mg/d ( n = 41), 300 mg/d ( n = 43), and 600 mg/d ( n = 41). Anthropometric and biochemical parameters were analyzed at baseline and 4 and 8 weeks. Resveratrol supplementation for 8 weeks did not significantly change the lipid profile compared with the placebo. However, a significant decrease of serum uric acid was observed at 8 weeks in 300 mg/d (−23.60 ± 61.53 μmol/L, p < 0.05) and 600 mg/d resveratrol groups (−24.37 ± 64.24 μmol/L, p < 0.01) compared to placebo (8.19 ± 44.60 μmol/L). Furthermore, xanthine oxidase (XO) activity decreased significantly in the 600 mg/d resveratrol group (−0.09 ± 0.29 U/mL, p < 0.05) compared with placebo (0.03 ± 0.20 U/mL) after 8 weeks. The reduction of uric acid and XO activity exhibited a dose–response relationship ( p for trend, <0.05). Furthermore, a marked correlation was found between the changes in uric acid and XO activity in the resveratrol groups ( r = 0.254, p < 0.01). Resveratrol (10 μmol/L) treatment to HepG2 cells significantly reduced the uric acid levels and intracellular XO activity. Nevertheless, we failed to detect significant differences in glucose, insulin, or oxidative stress biomarkers between the resveratrol groups and placebo. In conclusion, resveratrol supplementation for 8 weeks had no significant effect on lipid profile but decreased uric acid in a dose-response manner, possibly due to XO inhibition in subjects with dyslipidemia. The trial was registered on ClinicalTrials.gov (NCT04886297). |
| Audience | Academic |
| Author | Pan, Zhijun Li, Qing Pang, Juan Wang, Xin Zeng, Yupeng Yang, Yan Jin, Yufeng Ling, Wenhua Chen, Yu Zhou, Yuqing |
| AuthorAffiliation | 2 Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, China 4 Department of Nutrition, School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China 1 Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China 3 Guangdong Engineering Technology Center of Nutrition Transformation, Guangzhou 510080, China |
| AuthorAffiliation_xml | – name: 2 Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, China – name: 4 Department of Nutrition, School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China – name: 3 Guangdong Engineering Technology Center of Nutrition Transformation, Guangzhou 510080, China – name: 1 Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China |
| Author_xml | – sequence: 1 givenname: Yuqing surname: Zhou fullname: Zhou, Yuqing – sequence: 2 givenname: Yupeng surname: Zeng fullname: Zeng, Yupeng – sequence: 3 givenname: Zhijun surname: Pan fullname: Pan, Zhijun – sequence: 4 givenname: Yufeng surname: Jin fullname: Jin, Yufeng – sequence: 5 givenname: Qing surname: Li fullname: Li, Qing – sequence: 6 givenname: Juan surname: Pang fullname: Pang, Juan – sequence: 7 givenname: Xin surname: Wang fullname: Wang, Xin – sequence: 8 givenname: Yu surname: Chen fullname: Chen, Yu – sequence: 9 givenname: Yan orcidid: 0000-0002-5662-4600 surname: Yang fullname: Yang, Yan – sequence: 10 givenname: Wenhua surname: Ling fullname: Ling, Wenhua |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36771199$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1rHSEUhoeS0qRpNv0BReimFG7qjDqOm8Il_YQbUtJ0LY5zvNdbRyc6k5Iu-tvrkDRfBKoLD_icF33P-7zY8cFDUbws8SEhAr_zU8kwwVRUT4q9CvNqUdeU7Nypd4uDlLZ4XhzzmjwrdknNeVkKsVf8WaJT5bvQ29_QobNolUPBo1NIFxDVGIND36dhcNCDH9HSGNCj9Wu0soPt0LcYjHWAsgI6GTcQ0TGMqg3OanSs4k-ICVmfFdpt7kvolx036MNlcnM39Fa9KJ4a5RIcXJ_7xY9PH8-OvixWJ5-_Hi1XC81wPS5Ma5SmpTaaMcZpp3JhCGuIKHnbAJBS4aZrBQZctRWnWBuuKVBegzBNo8l-8f5Kd5jaHjqdPxOVk0O0vYqXMigr7994u5HrcCGFqLK_ZRZ4cy0Qw_kEaZS9TRqcUx7ClGSeACYNYaz6L1pxzuqyZhhn9PUDdBum6LMTM0UFzT8kt9RaOZDWm5CfqGdRueSUVIzkKWfq8BEq79lonUMzT-p-w6u7ntyY8S8cGXh7BegYUopgbpASyzl88jZ8GcYPYG1HNdow-2ndYy1_Ac-l20w |
| CitedBy_id | crossref_primary_10_1097_WCO_0000000000001184 crossref_primary_10_1080_87559129_2025_2453613 crossref_primary_10_1080_1028415X_2024_2425649 crossref_primary_10_1142_S0192415X24500733 crossref_primary_10_3390_endocrines5020016 crossref_primary_10_1007_s11883_023_01165_4 crossref_primary_10_3390_ijms25020747 crossref_primary_10_3390_medicina61010139 crossref_primary_10_3390_biom14121497 crossref_primary_10_3390_nu16071086 |
| Cites_doi | 10.1016/j.dld.2014.11.015 10.1016/j.phrs.2016.08.010 10.1002/mnfr.201100828 10.3109/09637486.2016.1174192 10.1016/j.mcna.2011.06.003 10.1016/j.ejmech.2019.07.020 10.1016/j.cgh.2014.02.024 10.5551/jat.33951 10.1016/j.clinbiochem.2017.07.013 10.2174/0929867311320100009 10.1161/CIRCULATIONAHA.107.703389 10.1186/1471-2458-4-9 10.1038/s41598-020-59925-0 10.1007/s10067-017-3559-z 10.3390/nu11030541 10.1002/med.21565 10.1113/jphysiol.2013.258061 10.1080/10408398.2020.1764487 10.1016/j.phrs.2017.12.033 10.1042/BSR20170939 10.1016/j.nut.2018.06.015 10.1016/j.redox.2021.102108 10.1016/j.biochi.2015.06.025 10.1039/D1FO00538C 10.1155/2019/6859757 10.1002/med.21742 10.1016/j.cca.2018.05.046 10.1016/j.jare.2016.11.004 10.2337/db21-0490 10.1016/j.cbi.2014.12.033 10.1016/j.jfma.2012.11.014 10.1016/j.fochx.2021.100146 10.2174/138161205774913255 10.1016/j.atherosclerosis.2007.03.008 10.1002/jsfa.10152 10.1016/j.phymed.2018.11.032 10.3390/nu12010161 10.3892/mmr.2021.12203 10.5603/KP.a2015.0024 10.1016/j.clnu.2021.02.004 10.1124/dmd.104.000885 10.1146/annurev-physiol-021113-170343 10.2337/diacare.27.12.3009 10.1002/clc.20511 10.1530/ERC-13-0171 10.1016/j.ijantimicag.2019.02.015 10.1155/2013/589169 10.3390/ijms22084210 10.1002/ptr.7002 10.1016/j.pharmthera.2016.12.004 10.2174/092986710791556032 10.1016/j.jnutbio.2018.07.014 10.1186/s12872-019-1026-2 10.1371/journal.pone.0118393 10.4162/nrp.2021.15.1.26 10.1053/j.gastro.2013.10.059 10.1016/j.biopha.2020.110026 10.3389/fphar.2020.568006 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2023 MDPI AG 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 by the authors. 2023 |
| Copyright_xml | – notice: COPYRIGHT 2023 MDPI AG – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 by the authors. 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TS 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM |
| DOI | 10.3390/nu15030492 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Physical Education Index Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Physical Education Index ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE AGRICOLA MEDLINE - Academic Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: Proquest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 2072-6643 |
| ExternalDocumentID | PMC9921501 A743253643 36771199 10_3390_nu15030492 |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | China Beijing China |
| GeographicLocations_xml | – name: China – name: Beijing China |
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 81730090, 81973022 – fundername: National Natural Science Foundation of China grantid: 81730090; 81973022 |
| GroupedDBID | --- 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AADQD AAFWJ AAHBH AAWTL AAYXX ABUWG ACIWK ACPRK AENEX AFKRA AFRAH AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS APEBS BENPR BPHCQ BVXVI CCPQU CITATION DIK E3Z EBD ECGQY EIHBH ESTFP EYRJQ F5P FYUFA GX1 HMCUK HYE IAO ITC KQ8 LK8 M1P M48 MODMG M~E OK1 OZF P2P P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM TR2 UKHRP CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7TS 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c506t-fbfac41cfc55574dafc5f3583917b8ee31a08db90e02b2740cf7c4e476e9f88c3 |
| IEDL.DBID | M48 |
| ISSN | 2072-6643 |
| IngestDate | Thu Aug 21 18:38:32 EDT 2025 Fri Sep 05 04:13:07 EDT 2025 Fri Sep 05 08:10:02 EDT 2025 Fri Jul 25 09:34:37 EDT 2025 Tue Jun 17 21:35:26 EDT 2025 Tue Jun 10 20:47:23 EDT 2025 Mon Jul 21 05:42:24 EDT 2025 Tue Jul 01 02:15:57 EDT 2025 Thu Apr 24 23:09:07 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | dyslipidemia resveratrol uric acid xanthine oxidase randomized controlled trial |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c506t-fbfac41cfc55574dafc5f3583917b8ee31a08db90e02b2740cf7c4e476e9f88c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| ORCID | 0000-0002-5662-4600 |
| OpenAccessLink | https://www.proquest.com/docview/2774948393?pq-origsite=%requestingapplication% |
| PMID | 36771199 |
| PQID | 2774948393 |
| PQPubID | 2032353 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9921501 proquest_miscellaneous_3040383552 proquest_miscellaneous_2775616500 proquest_journals_2774948393 gale_infotracmisc_A743253643 gale_infotracacademiconefile_A743253643 pubmed_primary_36771199 crossref_primary_10_3390_nu15030492 crossref_citationtrail_10_3390_nu15030492 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20230117 |
| PublicationDateYYYYMMDD | 2023-01-17 |
| PublicationDate_xml | – month: 1 year: 2023 text: 20230117 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Nutrients |
| PublicationTitleAlternate | Nutrients |
| PublicationYear | 2023 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Konno (ref_48) 2013; 2013 Haghighatdoost (ref_33) 2018; 129 Ekici (ref_10) 2015; 73 Lee (ref_20) 2021; 46 ref_57 ref_56 Carter (ref_25) 2014; 21 Salem (ref_2) 2017; 8 Ndrepepa (ref_13) 2018; 484 Wu (ref_31) 2020; 11 Apostolidou (ref_43) 2015; 67 Szkudelska (ref_23) 2020; 125 Chassot (ref_29) 2018; 61 Choi (ref_8) 2007; 116 Bloomgarden (ref_11) 2004; 27 Chachay (ref_58) 2014; 12 Chen (ref_3) 2017; 36 Zhang (ref_28) 2021; 35 Jayachandran (ref_36) 2021; 41 Li (ref_55) 2014; 146 Vestergaard (ref_21) 2019; 53 Wu (ref_19) 2019; 2019 ref_27 Bo (ref_49) 2016; 111 Kroon (ref_54) 2010; 17 Yousri (ref_12) 2022; 71 Singh (ref_32) 2019; 39 Franssen (ref_34) 2011; 95 Gu (ref_24) 2019; 180 Song (ref_17) 2018; 38 Liang (ref_53) 2019; 59 Shi (ref_45) 2012; 56 Ando (ref_9) 2016; 23 Nakagami (ref_47) 2019; 41 Lippi (ref_37) 2010; 33 Chen (ref_35) 2015; 47 Okafor (ref_18) 2017; 172 Shih (ref_5) 2015; 114 Glantzounis (ref_16) 2005; 11 ref_38 Zhang (ref_46) 2021; 24 Tian (ref_22) 2020; 100 Mandal (ref_15) 2015; 77 Xiao (ref_44) 2021; 15 Masuoka (ref_52) 2021; 12 Castro (ref_6) 2017; 50 Shaik (ref_26) 2020; 10 Katsiki (ref_1) 2021; 61 Gliemann (ref_40) 2013; 591 Tavil (ref_7) 2008; 197 ref_41 (ref_39) 2019; 58 Mansour (ref_42) 2021; 40 Walle (ref_59) 2004; 32 Lima (ref_14) 2015; 116 Li (ref_30) 2021; 12 Macedo (ref_51) 2015; 227 ref_4 Bo (ref_50) 2013; 20 |
| References_xml | – volume: 47 start-page: 226 year: 2015 ident: ref_35 article-title: Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial publication-title: Digest. Liver. Dis. doi: 10.1016/j.dld.2014.11.015 – volume: 111 start-page: 896 year: 2016 ident: ref_49 article-title: Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2016.08.010 – volume: 56 start-page: 1433 year: 2012 ident: ref_45 article-title: Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.201100828 – volume: 67 start-page: 541 year: 2015 ident: ref_43 article-title: Alterations of antioxidant status in asymptomatic hypercholesterolemic individuals after resveratrol intake publication-title: Int. J. Food Sci. Nutr. doi: 10.3109/09637486.2016.1174192 – volume: 95 start-page: 893 year: 2011 ident: ref_34 article-title: Obesity and dyslipidemia publication-title: Med. Clin. North. Am. doi: 10.1016/j.mcna.2011.06.003 – volume: 180 start-page: 62 year: 2019 ident: ref_24 article-title: Synthesis and assessment of phenylacrylamide derivatives as potential anti-oxidant and anti-inflammatory agents publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2019.07.020 – volume: 12 start-page: 2092 year: 2014 ident: ref_58 article-title: Resveratrol does not benefit patients with nonalcoholic fatty liver disease publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2014.02.024 – volume: 23 start-page: 932 year: 2016 ident: ref_9 article-title: Impact of Serum Uric Acid Levels on Coronary Plaque Stability Evaluated Using Integrated Backscatter Intravascular Ultrasound in Patients with Coronary Artery Disease publication-title: J. Atheroscler. Thromb. doi: 10.5551/jat.33951 – volume: 50 start-page: 1289 year: 2017 ident: ref_6 article-title: Effect of allopurinol and uric acid normalization on serum lipids hyperuricemic subjects: A systematic review with meta-analysis publication-title: Clin. Biochem. doi: 10.1016/j.clinbiochem.2017.07.013 – volume: 20 start-page: 1323 year: 2013 ident: ref_50 article-title: Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial publication-title: Curr. Med. Chem. doi: 10.2174/0929867311320100009 – volume: 116 start-page: 894 year: 2007 ident: ref_8 article-title: Independent impact of gout on mortality and risk for coronary heart disease publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.703389 – ident: ref_4 doi: 10.1186/1471-2458-4-9 – volume: 10 start-page: 3426 year: 2020 ident: ref_26 article-title: Combined cardio-protective ability of syringic acid and resveratrol against isoproterenol induced cardio-toxicity in rats via attenuating NF-kB and TNF-α pathways publication-title: Sci. Rep. doi: 10.1038/s41598-020-59925-0 – volume: 36 start-page: 1111 year: 2017 ident: ref_3 article-title: Association between the hypertriglyceridemic waist phenotype and hyperuricemia: A cross-sectional study publication-title: Clin. Rheumatol. doi: 10.1007/s10067-017-3559-z – ident: ref_56 doi: 10.3390/nu11030541 – volume: 39 start-page: 1851 year: 2019 ident: ref_32 article-title: Health benefits of resveratrol: Evidence from clinical studies publication-title: Med. Res. Rev. doi: 10.1002/med.21565 – volume: 591 start-page: 5047 year: 2013 ident: ref_40 article-title: Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men publication-title: J. Physiol. doi: 10.1113/jphysiol.2013.258061 – volume: 61 start-page: 1651 year: 2021 ident: ref_1 article-title: Dietary habits, lipoprotein metabolism and cardiovascular disease: From individual foods to dietary patterns publication-title: Crit. Rev. Food Sci. Nutr. doi: 10.1080/10408398.2020.1764487 – volume: 129 start-page: 141 year: 2018 ident: ref_33 article-title: Effect of resveratrol on lipid profile: An updated systematic review and meta-analysis on randomized clinical trials publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2017.12.033 – volume: 38 start-page: BSR20170939 year: 2018 ident: ref_17 article-title: Uric acid promotes oxidative stress and enhances vascular endothelial cell apoptosis in rats with middle cerebral artery occlusion publication-title: Biosci. Rep. doi: 10.1042/BSR20170939 – volume: 58 start-page: 7 year: 2019 ident: ref_39 article-title: Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial publication-title: Nutrition doi: 10.1016/j.nut.2018.06.015 – volume: 46 start-page: 102108 year: 2021 ident: ref_20 article-title: Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway publication-title: Redox. Biol. doi: 10.1016/j.redox.2021.102108 – volume: 116 start-page: 17 year: 2015 ident: ref_14 article-title: Uric acid as a modulator of glucose and lipid metabolism publication-title: Biochimie doi: 10.1016/j.biochi.2015.06.025 – volume: 12 start-page: 8274 year: 2021 ident: ref_30 article-title: Resveratrol, a novel inhibitor of GLUT9, ameliorates liver and kidney injuries in a D-galactose-induced ageing mouse model via the regulation of uric acid metabolism publication-title: Food Funct. doi: 10.1039/D1FO00538C – volume: 2019 start-page: 6859757 year: 2019 ident: ref_19 article-title: Relationships between Serum Uric Acid, Malondialdehyde Levels, and Carotid Intima-Media Thickness in the Patients with Metabolic Syndrome publication-title: Oxid. Med. Cell. Longev. doi: 10.1155/2019/6859757 – volume: 41 start-page: 616 year: 2021 ident: ref_36 article-title: Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence publication-title: Med. Res. Rev. doi: 10.1002/med.21742 – volume: 484 start-page: 150 year: 2018 ident: ref_13 article-title: Uric acid and cardiovascular disease publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2018.05.046 – volume: 8 start-page: 537 year: 2017 ident: ref_2 article-title: Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review publication-title: J. Adv. Res. doi: 10.1016/j.jare.2016.11.004 – volume: 71 start-page: 184 year: 2022 ident: ref_12 article-title: Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia publication-title: Diabetes doi: 10.2337/db21-0490 – volume: 227 start-page: 89 year: 2015 ident: ref_51 article-title: Effects of chronic resveratrol supplementation in military firefighters undergo a physical fitness test—a placebo-controlled, double blind study publication-title: Chem. Biol. Interact. doi: 10.1016/j.cbi.2014.12.033 – volume: 114 start-page: 314 year: 2015 ident: ref_5 article-title: Association between serum uric acid and nonalcoholic fatty liver disease in the US population publication-title: J. Formos. Med. Assoc. doi: 10.1016/j.jfma.2012.11.014 – volume: 12 start-page: 100146 year: 2021 ident: ref_52 article-title: Stilbene compounds are specific inhibitors of the superoxide anion generation catalyzed by xanthine oxidase publication-title: Food Chem. X doi: 10.1016/j.fochx.2021.100146 – volume: 11 start-page: 4145 year: 2005 ident: ref_16 article-title: Uric acid and oxidative stress publication-title: Curr. Pharm. Des. doi: 10.2174/138161205774913255 – volume: 197 start-page: 159 year: 2008 ident: ref_7 article-title: Uric acid level and its association with carotid intima-media thickness in patients with hypertension publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2007.03.008 – volume: 100 start-page: 1392 year: 2020 ident: ref_22 article-title: Resveratrol: A review of plant sources, synthesis, stability, modification and food application publication-title: J. Sci. Food Agric. doi: 10.1002/jsfa.10152 – volume: 59 start-page: 152772 year: 2019 ident: ref_53 article-title: Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice publication-title: Phytomedicine doi: 10.1016/j.phymed.2018.11.032 – ident: ref_57 doi: 10.3390/nu12010161 – volume: 24 start-page: 564 year: 2021 ident: ref_46 article-title: Resveratrol affects the expression of uric acid transporter by improving inflammation publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2021.12203 – volume: 73 start-page: 533 year: 2015 ident: ref_10 article-title: The relationship between serum uric acid levels and angiographic severity of coronary heart disease publication-title: Kardiol. Pol. doi: 10.5603/KP.a2015.0024 – volume: 40 start-page: 4106 year: 2021 ident: ref_42 article-title: Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS publication-title: Clin. Nutr. doi: 10.1016/j.clnu.2021.02.004 – volume: 32 start-page: 1377 year: 2004 ident: ref_59 article-title: High absorption but very low bioavailability of oral resveratrol in humans publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.104.000885 – volume: 77 start-page: 323 year: 2015 ident: ref_15 article-title: The molecular physiology of uric acid homeostasis publication-title: Annu. Rev. Physiol. doi: 10.1146/annurev-physiol-021113-170343 – volume: 27 start-page: 3009 year: 2004 ident: ref_11 article-title: Dyslipidemia and the metabolic syndrome publication-title: Diabetes Care doi: 10.2337/diacare.27.12.3009 – volume: 41 start-page: 125 year: 2019 ident: ref_47 article-title: Immunomodulatory and Metabolic Changes after Gnetin-C Supplementation in Humans publication-title: Int. J. Lab. Hematol. – volume: 33 start-page: E76 year: 2010 ident: ref_37 article-title: Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile publication-title: Clin. Cardiol. doi: 10.1002/clc.20511 – volume: 21 start-page: R209 year: 2014 ident: ref_25 article-title: Resveratrol and cancer: Focus on in vivo evidence publication-title: Endocr. Relat. Cancer doi: 10.1530/ERC-13-0171 – volume: 53 start-page: 716 year: 2019 ident: ref_21 article-title: Antibacterial and antifungal properties of resveratrol publication-title: Int. J. Antimicrob. Agents. doi: 10.1016/j.ijantimicag.2019.02.015 – volume: 2013 start-page: 589169 year: 2013 ident: ref_48 article-title: Melinjo (Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study publication-title: Evid-Based Compl. Alt. doi: 10.1155/2013/589169 – ident: ref_27 doi: 10.3390/ijms22084210 – volume: 35 start-page: 2945 year: 2021 ident: ref_28 article-title: Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis publication-title: Phytother. Res. doi: 10.1002/ptr.7002 – volume: 172 start-page: 139 year: 2017 ident: ref_18 article-title: Allopurinol as a therapeutic option in cardiovascular disease publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2016.12.004 – volume: 17 start-page: 2442 year: 2010 ident: ref_54 article-title: The Cardiovascular Nutrapharmacology of Resveratrol: Pharmacokinetics, Molecular Mechanisms and Therapeutic Potential publication-title: Curr. Med. Chem. doi: 10.2174/092986710791556032 – volume: 61 start-page: 48 year: 2018 ident: ref_29 article-title: Comparison between red wine and isolated trans-resveratrol on the prevention and regression of atherosclerosis in LDLr ((-/-)) mice publication-title: J. Nutr. Biochem. doi: 10.1016/j.jnutbio.2018.07.014 – ident: ref_38 doi: 10.1186/s12872-019-1026-2 – ident: ref_41 doi: 10.1371/journal.pone.0118393 – volume: 15 start-page: 26 year: 2021 ident: ref_44 article-title: Effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats publication-title: Nutr. Res. Pract. doi: 10.4162/nrp.2021.15.1.26 – volume: 146 start-page: 539 year: 2014 ident: ref_55 article-title: Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21 publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.10.059 – volume: 125 start-page: 110026 year: 2020 ident: ref_23 article-title: Resveratrol ameliorates inflammatory and oxidative stress in type 2 diabetic Goto-Kakizaki rats publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2020.110026 – volume: 11 start-page: 568006 year: 2020 ident: ref_31 article-title: Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m(6)A RNA Methylation publication-title: Front. Pharmacol. doi: 10.3389/fphar.2020.568006 |
| SSID | ssj0000070763 |
| Score | 2.393682 |
| Snippet | Resveratrol is a polyphenol with a well-established beneficial effect on dyslipidemia and hyperuricemia in preclinical experiments. Nonetheless, its efficacy... |
| SourceID | pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 492 |
| SubjectTerms | Biomarkers blood lipids Blood pressure blood serum Cholesterol Diet therapy Dietary Supplements dose response Double-Blind Method Dyslipidemias Dyslipidemias - drug therapy Glucose Health aspects High density lipoprotein Humans Hyperlipidemia hyperuricemia insulin Insulin resistance lipid composition Lipids Low density lipoprotein Medical research Metabolic disorders Oxidative stress Physiological aspects placebos polyphenols Protein expression Proteins Resveratrol Uric Acid Urine xanthine oxidase |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9UwDI9gXLigsfHRMZARCMShWj-Spj2hijFNSAM0bdK7VWk-xJPe0rH3HtI48Ldjp33dioBbpbhRGtvxz45rM_a6UMZVqdaxLdFF4YlFnTOtitHYZQYRtLQhdHHyuTg-559mYjYE3JZDWuXmTAwHtek0xcgPMsQpFUdznr-__B5T1yi6XR1aaNxl91KEKiTVcibHGEuoZVPkfVXSHL37A79GAEQ3S9nEDv15Gt8yR9NUyVu252ibPRhAI9Q9lx-yO9bvsN3ao8N8cQ1vIKRxhvj4LvtVw6nypruY_7QGzki-oPNwapc_qH7yVbeA0MkzhAWhDukcaL6Amlgb-Nq38AacAb4QNoQTu0I5Wcw10G89CBZh7nGGluI3S6AwLhxeI1jtO82qR-z86OPZh-N4aLIQa5EUq9i1TmmeaqeFEJIbhQ8uF7jRqWxLa_NUJci9KrFJ1qILm2gnNbdcFrZyZanzx2zLd94-ZcALi_gM_TeTOc6NU1XBhRGZqYQreaoi9m6z5Y0eKpBTI4xFg54Isae5YU_EXo20l33djb9SvSXONaSMOJNWwz8FuB7arKZGfJSJHFFXxPYnlKhEejq84X0zKPGyuRG5iL0ch-lNSkzztlsHGkSgCHOTf9PgUpMcka7A9T7pxWn8pryQEkW3ipicCNpIQOW_pyN-_i2UAa8qhGtJuvf_pT9j9zPEZRQ1SuU-21pdre1zxFGr9kVQlt-ssh_b priority: 102 providerName: ProQuest |
| Title | A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36771199 https://www.proquest.com/docview/2774948393 https://www.proquest.com/docview/2775616500 https://www.proquest.com/docview/3040383552 https://pubmed.ncbi.nlm.nih.gov/PMC9921501 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2072-6643 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: KQ8 dateStart: 20090101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2072-6643 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: DIK dateStart: 20090101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2072-6643 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: GX1 dateStart: 20090101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources (ISSN International Center) customDbUrl: eissn: 2072-6643 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2072-6643 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: RPM dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2072-6643 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2072-6643 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2072-6643 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0000070763 issn: 2072-6643 databaseCode: M48 dateStart: 20090901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdZ3fb9MwEMetsUloLwgYPzpGZQQC8RCWH3acPCAUYGNC6piqVepb5NiOqNQ5rD8Q5YG_na-TtFum7a2VL1bqO-c-d3XuCHkTS12mgVKeSRCiMN9gz-lCenB2oQZBC1OnLgan8cmIfR_z8RZZ9-9sF3B-a2jn-kmNZtMPfy5Xn7DhP7qIEyH7oV2CatzfRXgU78Ajhc66By3mNxgsEK5HTXXSG5fskvtRLETQVH-9ck03H9DXPFT39OQ1d3T8kDxoOZJmjeIfkS1jH5O9zCKGvljRt7Q-2VmnzPfIv4wOpdXVxeSv0fTcmRytLB2a-W9XUnlWTWnd3LPOFNKsPuEBj0ZdX2tNz5qu3hQz0B8OF-nALGA604mi7k0f8COdWMxQuJTOnLrMLv26Ar82zWflEzI6Pjr_cuK1fRc8xf144ZVFKRULVKk454JpiQ9lxIFSgSgSY6JA-lBo6hs_LBDV-qoUihkmYpOWSaKip2TbVtY8J5TFBsiGkE6HJWO6lGnMuOahTnmZsED2yPv1kueqLUruemNMcwQnTlP5laZ65PVG9ldTiuNWqXdOc7mzGMykZPuaAe7HLVaeAZlCHgHEeuSgI4l9pbrDa93na7PMQ9ByyrASGH61GXZXurNq1lTLWgZQCvL175bBrfoR4Jfjfp815rT5TWtz7BHRMbSNgKsI3h2xk591ZfA0BcH5wf6dc74guyEozeWQAnFAthezpXkJqloUfXJPjEWf7Hw-Oj0b4tu3cdCvt9F_IUYk8Q |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAFAeWxpYARL3GI6sR2HB8QWlGqLe0WVG2lvYXEdsRK26Tt7oKWAz-J38iMk00bBNx6i-SJ5XhmPN9MxjOEvIgzW-jQmMAl4KII5kDnbJ4FYOwiCwhaOR-6GB7Gg2PxcSzHa-TX6i4MplWuzkR_UNvKYIx8OwKcogWYc_7u9CzArlH4d3XVQqMWi323_A4u2-zt3g7w92UU7X4YvR8ETVeBwEgWz4MiLzIjQlMYKaUSNoOHgkuYOVR54hwPMwbL1cyxKAefjZlCGeGEip0uksRwmPcauS44E1irX41VG9PxtXNiXldB5Vyz7XIBgAv_ZEUdu_fn6X_J_HVTMy_Zut3b5FYDUmm_lqo7ZM2Vd8lGvwQH_WRJX1GfNurj8RvkZ58eZaWtTiY_nKUjlGdalfTIzb5hvebzakp951AfhqR9nz4C5pJi02xLP9ctwynMQD8hFqVDNwe5nE4MxWtEAE7ppIQZcowXzSiGjenOEsBx3dk2u0eOr2T775P1sirdQ0JF7AAPgr9oo0IIW2Q6FtLKyGpZJCLMeuTNastT01Q8x8Yb0xQ8H2RPesGeHnne0p7WdT7-SvUaOZei8sNMJmvuMMB6cLPSPuCxSHJAeT2y1aEEpTXd4RXv0-bQmKUXIt4jz9phfBMT4UpXLTwNIF6A1ezfNLBUxgFZS1jvg1qc2m_isVJhqHWPqI6gtQRYbrw7Uk6--rLjWgM8ZOHm_5f-lNwYjIYH6cHe4f4jcjMCTIgRq1BtkfX5-cI9Bgw3z594xaHky1Vr6m_kkl4Z |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkBAvCBgfHQOM-BIPUZPYjusHhCJKtTE2pmmT-hYSf4hKXbKtLag88Ifx13HnpNmCgLe9RfLVcX13vt9dzneEvEhy41SkdWAH4KLw0ILOmSIPwNjFBhC0tD50sbefbB_zj2MxXiO_VndhMK1ydSb6g9pUGmPk_RhwiuJgzlnfNWkRB8PRu9OzADtI4ZfWVTuNWkR27fI7uG-ztztD4PXLOB59OHq_HTQdBgItwmQeuMLlmkfaaSGE5CaHB8cEvCWSxcBaFuUhLF2FNowL8N9C7aTmlsvEKjcYaAbzXiPXJeMM08nkWLbxHV9HJ2F1RVTGVNgvFwC-8KtW3LGBf1qCS6awm6Z5ye6NbpNbDWClaS1hd8iaLe-SjbQEZ_1kSV9Rn0LqY_Mb5GdKD_PSVCeTH9bQI5RtWpX00M6-Ye3m82pKfRdRH5KkqU8lAdNJsYG2oQd1-3AKM9DPiEvpnp2DjE4nmuKVIgCqdFLCDAXGjmYUQ8h0uASgXHe5ze-R4yvZ_vtkvaxK-5BQnljAhuA7mthxblyuEi6MiI0SbsCjvEferLY80031c2zCMc3AC0L2ZBfs6ZHnLe1pXfPjr1SvkXMZHgQwk86b-wywHtysLAVsFgsGiK9HtjqUoMC6O7zifdYcILPsQtx75Fk7jL_EpLjSVgtPA-gXIHb4bxpYasgAZQtY74NanNr_xBIpo0ipHpEdQWsJsPR4d6ScfPUlyJUCqBhGm_9f-lNyA3Q0-7Szv_uI3IwBHmLwKpJbZH1-vrCPAc7Niydebyj5ctWK-hsJr2JU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Randomized+Trial+on+Resveratrol+Supplement+Affecting+Lipid+Profile+and+Other+Metabolic+Markers+in+Subjects+with+Dyslipidemia&rft.jtitle=Nutrients&rft.au=Zhou%2C+Yuqing&rft.au=Zeng%2C+Yupeng&rft.au=Pan%2C+Zhijun&rft.au=Jin%2C+Yufeng&rft.date=2023-01-17&rft.eissn=2072-6643&rft.volume=15&rft.issue=3&rft_id=info:doi/10.3390%2Fnu15030492&rft_id=info%3Apmid%2F36771199&rft.externalDocID=36771199 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6643&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6643&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6643&client=summon |